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The potential of stem cells as therapeutic, diagnostic, screening, and research tools has captured the
imagination of many researchers in academic and industry settings. A central role for industry in
the ongoing development of stem cell technologies is useful for both therapeutic applications and
the commercialization of technologies that support and drive the research. Appreciating such con-
tributions, the ISSCR appointed an Industry Committee in 2005 to provide international industry
representation and perspective to the Society’s activities. With the fast-paced progression of the
stem cell field, the role of the ISSCR Industry Committee is evolving.Industry has been a valuable component in the develop-
ment of stem cell technologies for more than two decades
(Marshak et al., 2001). The use of enriched populations of
hematopoietic stem cells for transplant was facilitated by
the development of devices and reagents for the selection
of cells from mobilized peripheral blood, and the clinical
use of such cells has become a standard in transplanta-
tion (Huntenburg et al., 1998). The acceptance of mesen-
chymal stem cells for research and therapeutic uses has
similarly been aided by commercial entities (Pittenger
et al., 1999). Other somatic tissue stem cells, such as
those from adipose tissue (Fraser et al., 2006), have
been transitioned from academic discovery to commercial
organizations.
Research involving embryonic stem (ES) cells has been
influenced by industry participation quite directly. For
example, because of the limitations on United States
government funding for human ES cell (hESC) research,
Geron Corporation was an important supporter of the
research that led to the isolation of hESC clones by James
Thomson and his colleagues (Thomson et al., 1998).
Industry sources, along with private foundations, have
continued to be vital to the development of hESC research
efforts. In addition to new cell lines, industry has commer-
cialized themedia, supplements, and substrates for grow-
ing ES cells, which has enabled many investigators to
enter the field. Outside the United States, hESC research
has expanded rapidly alongside other stem cell research,
in part due to less restrictive government regulations. The
United Kingdom, as one example, has seen the develop-
ment of several large centers of stem cell research, which
have spawned a significant number of companies associ-
ated with commercializing the ensuing technology. Public
funding of stem cell research in the United Kingdom has
enabled such links; for example, the Biotechnology & Bio-
logical Sciences Research Council funds programs at the
Roslin Institute that have contributed enormously to com-
mercial progress in animal stem cells. Australia, Singa-
pore, and South Korea are among other countries notable
in funding stem cell research.
The therapeutic, diagnostic, research, and screening
utility of stem cells has prompted many to imagine and
to realize products and product concepts for commercial-
ization. Such opportunities have attracted investment
from both the public and private equity markets. This
has infused a large amount of resources into companies,which fund internal research and development as well
as provide sponsorship for academic collaborators. In
this way, industry has participated in financing the efforts
for basic and applied research on stem cells, much in
the same way the industry has been involved in the de-
velopment of other biological technologies, such as re-
combinant therapeutic protein production, therapeutic
antibodies, gene therapy, and cell therapy. Stem cell tech-
nology differs from other technologies in that it is proving
fundamental to a variety of therapeutic and diagnostic
arenas, including the following: multiple disease areas
(e.g., cancer, cardiovascular disease, neurological dis-
eases, diabetes and metabolic disorders, autoimmune
disease, orthopaedic disorders); various delivery systems
(e.g., cell therapy, medical devices, transplantation); and
many uses in screening (e.g., toxicology, efficacy of
chemicals or biologics). In short, questions about stem
cells underlie many fundamental questions of biology
and therefore touch all medical and biological research.
The ISSCR leadership recognizes the key contributions
and ongoing participation of industry in stem cell research
and the value for the development of therapeutic and diag-
nostic applications in drawing together basic, clinical, and
industrial research arms. In 2005 the ISSCR leadership
conceived of an Industry Committee to provide counsel
on the commercial sector. I was invited to serve as the first
chairman of the Industry Committee, and with the ISSCR
leadership recruited representatives from commercial
organizations involved in therapeutics, diagnostics, re-
search tools, manufacturing, and venture capital. We
also attempted to draw in committee members represent-
ing each major geographical region of the world in which
extensive stem cell research is conducted in an industrial
setting. These included North America, Europe, Asia, and
Australia. All of the committee members had both techni-
cal scientific background and significant industrial experi-
ence and position. The committee was not intended to be
a marketing or fundraising organization, and committee
participation was not linked to sponsorship of the Society.
This status permitted the committee members to address
questions and issues fundamental to the relationship be-
tween the academic and industrial members of ISSCR
without a specific corporate agenda, but with an altruistic
and sincere interest in stem cell research.
Initially, the committee met quarterly to discuss how is-
sues in stem cell research affecting industry might beCell Stem Cell 1, October 2007 ª2007 Elsevier Inc. 387
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ISSCR is the annual meeting, and the Industry Committee
recommended to the Program Committee a variety of
qualified speaker candidates from the ranks of re-
searchers in industry to be considered for podium presen-
tations at the annual meetings. In addition to these candi-
dates the committee suggested several session topics on
technologies related to industry, intended to complement
the academic program. Examples of suggested sessions
included such subjects as Culture Media, Process Devel-
opment, Cell Manufacturing, Regulatory Affairs, and Clin-
ical Trial Design, as related to cell-based therapy. Further,
the committee supported increased reporting on clinical
progress in cellular therapies. To this end, the committee
has seen only limited success. To a large extent, this is
due to the fact that the stem cell therapy field is still early
in its development, and the ISSCR has focused on the un-
derlying scientific issues surrounding stem cells rather
than their applications. As the stem cell field matures,
the industry-related topics will have increasing relevance
to the ISSCR membership.
During 2007, the Industry Committee provided guid-
ance to other committees of the ISSCR, notably the Stan-
dards Committee. Members of the industrial community
have a significant stake in understanding and commenting
on standards that may be set by the community of scien-
tists in the stem cell field. Criteria for cell identity and pu-
rity, for example, are important to determine for cellular
products. In the laboratory, determining what standard
preparations will be acceptable to the academic commu-
nity is a key to supplying scientists with useful products,
which in turn is a key to operating a successful business
in research tools. In the clinic, demonstrating safety and
efficacy of preparations for therapeutic use is essential
to obtaining regulatory approval of cellular products. Cri-
teria for cellular preparations used in academic research
and those used in clinical products might be very different.
Further, large-scale manufacturing of therapeutic prod-
ucts may demand quite different technology than labora-
tory-scale research preparation. Thus, industry members
can contribute significant information and a critical per-
spective into themix of factors under consideration for as-
signing standards in stem cell research.
From an administrative point of view, the Industry Com-
mittee has offered several useful ideas to the ISSCRmem-
bership. Employment is an important concern for many
students and young investigators in the field, and the com-
mittee held ‘‘Meet the Experts’’ sessions in which mem-388 Cell Stem Cell 1, October 2007 ª2007 Elsevier Inc.bers can learn about employment opportunities in indus-
try. In the future, ISSCR may be able to mount a full
employment matching program to align scientists with
job interviews during the annual conference. The repre-
sentation of industry at future annual meetings of the
ISSCR will include an Industry Symposium Program prior
to the start of the conference. This model was recommen-
ded by several Industry Committee members, based on
good experiences with such sessions at the American So-
ciety of Hematology annual meetings. For 2008, the pro-
gram will be held on the Wednesday morning (June 11)
preceding the ISSCR annual meeting (June 11–14) in Phil-
adelphia.
As the stem cell field and the ISSCR have grown, so has
the Industry Committee matured and evolved in thinking
about and participating in the activities of the Society.
Ultimately, I advocate the goal of moving away from an
Industry Committee entirely. Instead I recommend
that members of the industrial scientific community be in-
corporated as full members of other committees. Rather
than isolating industry as a separate entity, allowing indus-
try participation in all of the functions of the ISSCR can
only add depth and needed perspective to the group,
forging useful scientific alloys that are stronger and more
useful than the base metals from which they rise.
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